advertise

Monday 22 September 2014

Adaptive Licensing - A Holistic Approach to Drug Development and Regulation - Global Industry size, share, trend, forecast, Analysis and growth

Adaptive Licensing (AL) is a flexible approach to drug development and regulation, with two live pilot schemes accepted by the European Medicines Agency (EMA). The system acknowledges that levels of uncertainty will always surround innovative treatments. An initial license is granted at an earlier stage than possible under the traditional system, with less clinical information from Randomized Controlled Trials (RCTs). After the initial license is granted, the entry to market is heavily restricted, and the patient population is carefully monitored through observational studies, electronic devices and registries. Data from ongoing RCTs, and the more robust data from post-license surveillance studies are used to determine full license permission. By improving the alignment of stakeholder needs in a fluid system, overall costs and patient access times can be reduced. However, uncertainty still exists around the approach, and it is clear that cultural and political changes will be necessary to realize the full potential of AL.

To Brows a Full Report with Toc: http://www.researchmoz.us/adaptive-licensing-a-holistic-approach-to-drug-development-and-regulation-report.html

Scope

Adaptive Licensing: Overview
Introduction
A Declining Industry ¬タモ How AL can tackle issues with the current system
Strengths
Challenges for AL
Proponents
Current Adaptive Licensing

Scope

Precursors ¬タモ Current systems within the traditional drug licensing framework that will act as facilitators to AL
Legality ¬タモ Feasibility of AL across different jurisdictions
Employing Adaptive Licensing ¬タモ EMA pilot scheme information, practical strategies
Future Adaptive Licensing
Transformative Strategies ¬タモ Future utility of AL requiring legislative change
Commercial Considerations
Pricing and Reimbursement with AL
Market Exclusivity
Achieving Value through AL
Value-at-risk
Key Reasons to Purchase

Adaptive Licensing is a highly current topic. In March 2014, the EMA (European Medicines Agency) began to invite drug developers to apply for involvement in the pilot projects.
Currently, two drug development programs have been accepted by the EMA as pilots. Three were rejected, four are in reserve and 11 are still under consideration.
AL is part of a suite of global initiatives with shared features. These include: Staggered Approval, Progressive Authorisation, Conditional Licensing and, more recently, Medicines Adaptive Pathways (MAPs) or Medicines Adaptive Pathways to Patients (MAPPs).
The high level of variance in AL approaches and scarcity of practical information justifies the need for an unbiased report of the strengths, weaknesses and opportunities for this system.
If pilots are successful, AL may become more widely used across all regions, and also play an important role in shaping future regulatory policy, with the potential to affect all healthcare stakeholders.
This new CBR report examines all existing information, and builds on that with conference attendance and new primary research with KOLs and figures central to the movement. It creates a balanced view, and provides an understanding of the current status and potential implications.


All Repoers of this Category Here: http://www.researchmoz.us/pharmaceutical-market-reports-38.html


About ResearchMoz

ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

Contact US: 


For More Information Kindly Contact:
Email: sales@researchmoz.us
Website @ http://www.researchmoz.us/

No comments:

Post a Comment